B-cell Lymphoma Clinical Trials

19 studies are recruiting for b-cell lymphoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

   To learn if giving mosunetuzumab in combination with polatuzumab vedotin, tafasitamab, and lenalidomide can help to control relapsed/refractory FL and DLBCL.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT05615636 on ClinicalTrials.gov

2. A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

   The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Alabama At Birmingham Hospital, Birmingham, Alabama

   Locations

   155 in total

   Run by

   BeOne Medicines

   See if you can join NCT06742996 on ClinicalTrials.gov

3. A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

   The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with tacabrutideg in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with sep…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic Phoenix, Phoenix, Arizona

   Locations

   49 in total

   Run by

   BeOne Medicines

   See if you can join NCT06634589 on ClinicalTrials.gov

4. A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

   The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope, Duarte, California

   Locations

   51 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07101328 on ClinicalTrials.gov

5. Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma

   The goal of this observational cohort study is to learn how toxin and occupational exposures, germline genetic variation, and immune dysregulation relate to B-cell non-Hodgkin lymphoma among active-duty service members and other Military Health System beneficiaries. The main questions are whether s…

   Stage

   Not phased

   Ages

   4 and older

   Site

   Walter Reed National Military Medical Center, Bethesda, Maryland

   Locations

   3 in total

   Run by

   Henry M. Jackson Foundation for the Advancement of Military Medicine

   See if you can join NCT07652580 on ClinicalTrials.gov

6. Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

   The study will evaluate the efficacy and safety of NX-5948 (bexobrutideg) versus pirtobrutinib in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who are relapsed or refractory to prior covalent Bruton tyrosine kinase inhibitor (cBTKi)…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Central Georgia Cancer Care, Macon, Georgia

   Locations

   6 in total

   Run by

   Nurix Therapeutics, Inc.

   See if you can join NCT07516093 on ClinicalTrials.gov

7. Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

   The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Rocky Mountain Cancer Centers, Aurora, Colorado

   Locations

   6 in total

   Run by

   Nurix Therapeutics, Inc.

   See if you can join NCT07520006 on ClinicalTrials.gov

8. Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

   BrUOG-401 is a prospective, single-arm, phase 2 trial of first-line therapy in adult patients with previously untreated FL or MZL. All patients will be assigned the same initial treatment plan, modified by interim response assessment (IRA) after Cycle 4. All patients will start treatment with four …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

   Locations

   3 in total

   Run by

   Brown University

   See if you can join NCT04792502 on ClinicalTrials.gov

9. A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

   To learn if the combination of axicabtagene ciloleucel (axi-cel) and glofitamab as first-line therapy in high-risk LBCL participants or as second-line therapy in LBCL participants can help to control the disease.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06213311 on ClinicalTrials.gov

10. Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

    The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma. Immune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells.…

    Stage

    Phase 1

    Ages

    12 to 80

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05092451 on ClinicalTrials.gov

11. CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

    Background: Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now be cured. But if the disease comes back, the survival rate drops to less than 50%. Better treatments are needed for ALL relapses. Objective: T…

    Stage

    Phase 1

    Ages

    3 to 39

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT05442515 on ClinicalTrials.gov

12. IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

    This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lympho…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Westmead Hospital, Westmead, New South Wales

    Locations

    13 in total

    Run by

    Iksuda Therapeutics Ltd.

    See if you can join NCT05365659 on ClinicalTrials.gov

13. Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

    The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, n…

    Stage

    Not phased

    Ages

    0 to 38

    Site

    Children's Hospital Colorado, Aurora, Colorado

    Locations

    5 in total

    Run by

    Children's Hospital Medical Center, Cincinnati

    See if you can join NCT06131801 on ClinicalTrials.gov

14. Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

    Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT). If patients achieve either complete, partial, or stable response following ASCT, they will receive an IV dose of Polatuzumab Vedotin once every 21 days until they receive…

    Stage

    Phase 1

    Ages

    12 to 70

    Site

    New York Medical Center, Valhalla, New York

    Run by

    New York Medical College

    See if you can join NCT04491370 on ClinicalTrials.gov

15. SynKIR-310 for Relapsed/Refractory B-NHL

    This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute, Denver, Colorado

    Locations

    5 in total

    Run by

    Verismo Therapeutics

    See if you can join NCT06544265 on ClinicalTrials.gov

16. A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL

    This is a Phase II single-center open label trial of the combination of ATRA and pembrolizumab treatment in patients with histologically proven, relapsed or refractory Hodgkin Lymphoma or B-Non-Hodgkin-lymphoma.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana

    Locations

    2 in total

    Run by

    Rita Assi

    See if you can join NCT06484920 on ClinicalTrials.gov

17. Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

    The purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Run by

    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT06350318 on ClinicalTrials.gov

18. A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

    This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Kansas, Westwood, Kansas

    Locations

    7 in total

    Run by

    CRISPR Therapeutics AG

    See if you can join NCT05643742 on ClinicalTrials.gov

19. Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

    This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.

    Stage

    Phase 2

    Ages

    18 to 79

    Site

    AHN Cancer Institute - West Penn Hospital, Pittsburgh, Pennsylvania

    Run by

    John Lister

    See if you can join NCT05281809 on ClinicalTrials.gov